MIMESIS NEWSLETTER #2, December 2017
A novel systems biology approach to develop preclinical assets from innovative drug discovery starting points inspired by viruses.
MIMESIS is a research and innovation project coordinated by ENYO Pharma and funded under the highly selective H2020 – SMEInstrument – Phase 2 call that aims at: “Dedicated support to biotechnology SMEs closing the gap from lab to market”. The MIMESIS project was launched on Nov 2016 for 2 years.
ENYO Pharma is pleased to announce the initiation of a research collaboration with Professor Julian Walters at Imperial College London. The main goal of these investigations is to evaluate the potential for therapeutic use of the FXR agonist EYP001. Explants of human ileum from healthy subjects will be exposed to increasing concentrations of ENYO Pharma’s FXR agonist.
ENYO Pharma is pleased to join The Liver Forum at the Forum for Collaborative Research, “to advance the regulatory sciences for the treatment of NASH and liver fibrosis, which is emerging as a leading cause of advanced liver disease in the U.S. and worldwide” (http://www.forumresearch.org/projects/liver-forum). The Liver Forum provides an independent and neutral venue for ongoing multi-stakeholder dialogue. This project will allow our biotech to participate in fruitful meetings and discussions focused on advancing the regulatory sciences for the treatment of NASH and liver fibrosis.
Initiation of a collaboration with Paris-Diderot University to discover new drugs against adenoviruses
ENYO Pharma announces its collaboration with Paris-Diderot University, Inserm Unit U941 (Institut Universitaire d’Hématologie), leaded by IDF Innov SATT, to discover new drugs against adenoviruses. The collaboration, built upon ENYO Pharma’s unique approach inspired by viruses, will identify new human cellular targets and pathway essential for replication of adenoviruses. This information will help to select experimental or clinical-stage small molecules that will be tested in a drug repositioning strategy. ENYO pharma will provide its peptide and small molecule libraries to the University team which will screen and analyse their impact on adenoviruses’